Clinical Trial: A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1

U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07179640) titled 'A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1' on Aug. 04.

Brief Summary: This is a phase 1/2a randomised, placebo controlled, double-blind study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALE1 on healthy adult subjects and adult patients with Hypophosphatasia (HPP).

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Hypophosphatasia (HPP)

Intervention: DRUG: ALE1

Specified dose on specified days

DRUG: Placebo

Specified dose on specifie...